Evidence map›Paper›PMID 39009898›Full record

ArticleJournal of cancer research and clinical oncology2024

What does "urgency" mean when prioritizing cancer treatment? Results from a qualitative study with German oncologists and other experts during the COVID-19 pandemic.

Sabine Sommerlatte, Helene Hense, Stephan Nadolny, Anna-Lena Kraeft, Celine Lugnier, Jochen Schmitt, Olaf Schoffer, Anke Reinacher-Schick, Jan Schildmann

Abstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Operationalizing urgency in oncology: ethical challenges amidst the pandemic.Journal of cancer research and clinical oncology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sabine SommerlatteInstitute for History and Ethics of Medicine, Interdisciplinary Center for Health Sciences, Medical Faculty, Martin Luther University Halle-Wittenberg, Magdeburger Str. 8, 06112, Halle (Saale), Germany. sabine.sommerlatte@medizin.uni-halle.de.ORCID http://orcid.org/0000-0001-6239-4349
Helene HenseCenter for Evidence-Based Healthcare, Medical Faculty and University Hospital Carl Gustav Carus , TUD Dresden University of Technology, Dresden, Germany.
Stephan NadolnyInstitute for History and Ethics of Medicine, Interdisciplinary Center for Health Sciences, Medical Faculty, Martin Luther University Halle-Wittenberg, Magdeburger Str. 8, 06112, Halle (Saale), Germany.
Anna-Lena KraeftDepartment of Hematology, Oncology and Palliative Care, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.
Celine LugnierDepartment of Hematology, Oncology and Palliative Care, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.
Jochen SchmittCenter for Evidence-Based Healthcare, Medical Faculty and University Hospital Carl Gustav Carus , TUD Dresden University of Technology, Dresden, Germany.
Olaf SchofferCenter for Evidence-Based Healthcare, Medical Faculty and University Hospital Carl Gustav Carus , TUD Dresden University of Technology, Dresden, Germany.
Anke Reinacher-SchickDepartment of Hematology, Oncology and Palliative Care, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.
Jan SchildmannInstitute for History and Ethics of Medicine, Interdisciplinary Center for Health Sciences, Medical Faculty, Martin Luther University Halle-Wittenberg, Magdeburger Str. 8, 06112, Halle (Saale), Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCancer care in Germany during the COVID-19 pandemic was affected by resource scarcity and the necessity to prioritize medical measures. This study explores ethical criteria for prioritization and their application in cancer practices from the perspective of German oncologists and other experts.

methodsWe conducted fourteen semi-structured interviews with German oncologists between February and July 2021 and fed findings of interviews and additional data on prioritizing cancer care into four structured group discussions, in January and February 2022, with 22 experts from medicine, nursing, law, ethics, health services research and health insurance. Interviews and group discussions were digitally recorded, transcribed verbatim and analyzed using qualitative content analysis.

resultsNarratives of the participants focus on "urgency" as most acceptable criterion for prioritization in cancer care. Patients who are considered curable and those with a high level of suffering, were given a high degree of "urgency." However, further analysis indicates that the "urgency" criterion needs to be further distinguished according to at least three different dimensions: "urgency" to (1) prevent imminent harm to life, (2) prevent future harm to life and (3) alleviate suffering. In addition, "urgency" is modulated by the "success," which can be reached by means of an intervention, and the "likelihood" of reaching that success.

conclusionOur analysis indicates that while "urgency" is a well-established criterion, its operationalization in the context of oncology is challenging. We argue that combined conceptual and clinical analyses are necessary for a sound application of the "urgency" criterion to prioritization in cancer care.

Indexed as

COVID-19NeoplasmsOncologistsQualitative ResearchAdultFemaleGermanyHealth PrioritiesHumansMaleMedical OncologyMiddle AgedPandemicsSARS-CoV-2Cancer careEmpirical bioethicsPandemicPrioritization criteriaResource allocationUrgency

Identifiers

PMID39009898
PMCPMC11249432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.